451 related articles for article (PubMed ID: 30641802)
1. Diabetic nephropathy: An update on pathogenesis and drug development.
A/L B Vasanth Rao VR; Tan SH; Candasamy M; Bhattamisra SK
Diabetes Metab Syndr; 2019; 13(1):754-762. PubMed ID: 30641802
[TBL] [Abstract][Full Text] [Related]
2. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
Zain M; Awan FR
Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
4. Targeting inflammation in diabetic nephropathy: a tale of hope.
Moreno JA; Gomez-Guerrero C; Mas S; Sanz AB; Lorenzo O; Ruiz-Ortega M; Opazo L; Mezzano S; Egido J
Expert Opin Investig Drugs; 2018 Nov; 27(11):917-930. PubMed ID: 30334635
[TBL] [Abstract][Full Text] [Related]
5. Management of diabetic nephropathy: Recent progress and future perspective.
Ahmad J
Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic agents in diabetic nephropathy.
Kim Y; Park CW
Korean J Intern Med; 2017 Jan; 32(1):11-25. PubMed ID: 28049280
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways in diabetic nephropathy.
Kawanami D; Matoba K; Utsunomiya K
Histol Histopathol; 2016 Oct; 31(10):1059-67. PubMed ID: 27094540
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.
Lv M; Chen Z; Hu G; Li Q
Drug Discov Today; 2015 Mar; 20(3):332-46. PubMed ID: 25448752
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
Kumar Pasupulati A; Chitra PS; Reddy GB
Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update.
Bhattacharjee N; Barma S; Konwar N; Dewanjee S; Manna P
Eur J Pharmacol; 2016 Nov; 791():8-24. PubMed ID: 27568833
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.
Samsu N
Biomed Res Int; 2021; 2021():1497449. PubMed ID: 34307650
[TBL] [Abstract][Full Text] [Related]
12. Role of growth factors in diabetic kidney disease.
Chiarelli F; Gaspari S; Marcovecchio ML
Horm Metab Res; 2009 Aug; 41(8):585-93. PubMed ID: 19452424
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Block TJ; Batu D; Cooper ME
Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease.
Araki SI
J Diabetes Investig; 2020 Jan; 11(1):22-24. PubMed ID: 31520446
[No Abstract] [Full Text] [Related]
15. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
[TBL] [Abstract][Full Text] [Related]
16. Diabetic nephropathy: protective factors and a new therapeutic paradigm.
Mima A
J Diabetes Complications; 2013; 27(5):526-30. PubMed ID: 23619194
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress.
Deng X; Cheng J; Shen M
J Endocrinol Invest; 2016 Jun; 39(6):657-66. PubMed ID: 26691308
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Nephropathy: a Tangled Web to Unweave.
Magee C; Grieve DJ; Watson CJ; Brazil DP
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):579-592. PubMed ID: 28956186
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.
Rayego-Mateos S; Morgado-Pascual JL; Opazo-Ríos L; Guerrero-Hue M; García-Caballero C; Vázquez-Carballo C; Mas S; Sanz AB; Herencia C; Mezzano S; Gómez-Guerrero C; Moreno JA; Egido J
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471207
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid improves diabetic nephropathy via suppression of oxidative stress and inflammation in streptozotocin-induced rats.
Xu HL; Wang XT; Cheng Y; Zhao JG; Zhou YJ; Yang JJ; Qi MY
Biomed Pharmacother; 2018 Sep; 105():915-921. PubMed ID: 30021385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
